Recurrent Osteosarcoma Recruiting Phase 2 Trials for Regramostim (DB05386)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02502786Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaTreatment